Literature DB >> 23012429

β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway.

Heddie L Nichols1, Mahmoud Saffeddine, Barbara S Theriot, Akhil Hegde, Daniel Polley, Tamer El-Mays, Harissios Vliagoftis, Morley D Hollenberg, Emma H Wilson, Julia K L Walker, Kathryn A DeFea.   

Abstract

Proteinase-Activated receptor-2 (PAR(2)), a G-protein-coupled Receptor, activated by serine proteinases, is reported to have both protective and proinflammatory effects in the airway. Given these opposing actions, both inhibitors and activators of PAR(2) have been proposed for treating asthma. PAR(2) can signal through two independent pathways: a β-arrestin-dependent one that promotes leukocyte migration, and a G-protein/Ca(2+) one that is required for prostaglandin E(2) (PGE(2)) production and bronchiolar smooth muscle relaxation. We hypothesized that the proinflammatory responses to PAR(2) activation are mediated by β-arrestins, whereas the protective effects are not. Using a mouse ovalbumin model for PAR(2)-modulated airway inflammation, we observed decreased leukocyte recruitment, cytokine production, and mucin production in β-arrestin-2(-/-) mice. In contrast, PAR(2)-mediated PGE(2) production, smooth muscle relaxation, and decreased baseline airway resistance (measures of putative PAR(2) "protective" effects) were independent of β-arrestin-2. Flow cytometry and cytospins reveal that lung eosinophil and CD4 T-cell infiltration, and production of IL-4, IL-6, IL-13, and TNFα, were enhanced in wild-type but not β-arrestin-2(-/-) mice. Using the forced oscillation technique to measure airway resistance reveals that PAR(2) activation protects against airway hyperresponsiveness by an unknown mechanism, possibly involving smooth muscle relaxation. Our data suggest that the PAR(2)-enhanced inflammatory process is β-arrestin-2 dependent, whereas the protective anticonstrictor effect of bronchial epithelial PAR(2) may be β-arrestin independent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23012429      PMCID: PMC3478622          DOI: 10.1073/pnas.1208881109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2).

Authors:  Rithwik Ramachandran; Koichiro Mihara; Hyunjae Chung; Bernard Renaux; Chang S Lau; Daniel A Muruve; Kathryn A DeFea; Michel Bouvier; Morley D Hollenberg
Journal:  J Biol Chem       Date:  2011-05-16       Impact factor: 5.157

2.  Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma.

Authors:  D A Knight; S Lim; A K Scaffidi; N Roche; K F Chung; G A Stewart; P J Thompson
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

3.  Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles.

Authors:  John J McGuire; Morley D Hollenberg; Patricia Andrade-Gordon; Chris R Triggle
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

4.  2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.

Authors:  John J McGuire; Mahmoud Saifeddine; Chris R Triggle; Kimberly Sun; Morley D Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2004-02-19       Impact factor: 4.030

5.  Beta-arrestin-2 regulates the development of allergic asthma.

Authors:  Julia K L Walker; Alan M Fong; Barbara L Lawson; Jordan D Savov; Dhavalkumar D Patel; David A Schwartz; Robert J Lefkowitz
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

6.  Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma.

Authors:  Zsuzsanna Callaerts-Vegh; Kenda L J Evans; Noornabi Dudekula; Donald Cuba; Brian J Knoll; Patrick F K Callaerts; Heather Giles; Felix R Shardonofsky; Richard A Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-06       Impact factor: 11.205

7.  A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis.

Authors:  Lan Ge; Youly Ly; Morley Hollenberg; Kathryn DeFea
Journal:  J Biol Chem       Date:  2003-06-23       Impact factor: 5.157

8.  Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway.

Authors:  Fabien Schmidlin; Silvia Amadesi; Karim Dabbagh; David E Lewis; Patrick Knott; Nigel W Bunnett; Paul R Gater; Pierangelo Geppetti; Claude Bertrand; Mary E Stevens
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

9.  Proteinase-activated receptor-2 mediates hyperresponsiveness in isolated guinea pig bronchi.

Authors:  Victor E Barrios; Mark A Jarosinski; Clifford D Wright
Journal:  Biochem Pharmacol       Date:  2003-08-01       Impact factor: 5.858

10.  beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2.

Authors:  K A DeFea; J Zalevsky; M S Thoma; O Déry; R D Mullins; N W Bunnett
Journal:  J Cell Biol       Date:  2000-03-20       Impact factor: 10.539

View more
  41 in total

1.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

Review 2.  β-Arrestins 1 and 2 are critical regulators of inflammation.

Authors:  Hongkuan Fan
Journal:  Innate Immun       Date:  2013-09-12       Impact factor: 2.680

Review 3.  Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.

Authors:  M D Hollenberg; K Mihara; D Polley; J Y Suen; A Han; D P Fairlie; R Ramachandran
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

4.  Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.

Authors:  Jeffrey S Smith; Lowell T Nicholson; Jutamas Suwanpradid; Rachel A Glenn; Nicole M Knape; Priya Alagesan; Jaimee N Gundry; Thomas S Wehrman; Amber Reck Atwater; Michael D Gunn; Amanda S MacLeod; Sudarshan Rajagopal
Journal:  Sci Signal       Date:  2018-11-06       Impact factor: 8.192

5.  Epithelial Cells Induce a Cyclo-Oxygenase-1-Dependent Endogenous Reduction in Airway Smooth Muscle Contractile Phenotype.

Authors:  Michael J O'Sullivan; Elizabeth Gabriel; Alice Panariti; Chan Y Park; Gijs Ijpma; Jeffrey J Fredberg; Anne-Marie Lauzon; James G Martin
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

Review 6.  The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Authors:  Yuri K Peterson; Louis M Luttrell
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

7.  Genetic Deletion of β-Arrestin-2 and the Mitigation of Established Airway Hyperresponsiveness in a Murine Asthma Model.

Authors:  Minyong Chen; Akhil Hegde; Yeon Ho Choi; Barbara S Theriot; Richard T Premont; Wei Chen; Julia K L Walker
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

8.  IL-13 desensitizes β2-adrenergic receptors in human airway epithelial cells through a 15-lipoxygenase/G protein receptor kinase 2 mechanism.

Authors:  Giusy D Albano; Jinming Zhao; Emily B Etling; Seo Young Park; Haizhen Hu; John B Trudeau; Mirella Profita; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2015-03-24       Impact factor: 10.793

Review 9.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

10.  GPCRs and arrestins in airways: implications for asthma.

Authors:  Raymond B Penn; Richard A Bond; Julia K L Walker
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.